

Curriculum Vitae

Name: **Jed E. Rose, Ph. D.**
Title: Director, Duke Center for Nicotine & Smoking Cessation Research

Address: 2424 Erwin Road, Suite 201, Hock Plaza
 Durham, NC 27705
 Tel: (919) 668-5055
 Fax: (919) 668-5088
 E-mail: rose0003@mc.duke.edu

Personal:

Place Birth:
Citizen: USA

Education:

College:	1969-1973	University of California, Berkeley B.A. (with great distinction) in Physics
Graduate:	1973-1978	University of California, San Diego Ph.D. in Neurosciences
	1978-1979	University of California, Los Angeles Postdoctoral work in Psychophysiology

Awards

1969	Regents Scholarship, U.C. Berkeley
1972	Phi Beta Kappa (entered in Junior year)
1974-1975	Alfred P. Sloan Predoctoral Fellowship
1975-1978	USPHS Predoctoral Traineeship
1979-1980	NIMH Postdoctoral Fellowship

Employment

1998-present	Medical Research Professor Department of Psychiatry Duke University
1989-2004	Chief, Nicotine Research Laboratory VA Medical Center Durham
1989-1998	Associate Medical Research Professor Department of Psychiatry Duke University

1983-1988	Chief, Nicotine Research Laboratory VA Medical Center Brentwood
1986-1988	Associate Research Psychologist Department of Psychiatry, UCLA
1981-1988	Research Psychologist VA Medical Center Brentwood
1980-1986	Assistant Research Psychologist Department of Psychiatry, UCLA
1978-1981	Consultant, Psychopharmacology Unit VA Medical Center Brentwood

Memberships in Professional Organizations

Society for Neuroscience
American Psychological Association
Society for Research on Nicotine and Tobacco (charter member)
American College of Neuropsychopharmacology
Honorary Member of the World Innovation Foundation

Editorial and grant review service

Grant review panels for National Institute on Drug Abuse and California Tobacco-Related Disease Program

Member of NCI/NIDA working group on Pharmacologic Approaches to the Treatment of Nicotine Addiction

Regular reviewer for: Psychopharmacology; American Journal of Psychiatry; Biological Psychiatry; Drug and Alcohol Dependence; Neuropsychopharmacology; Nicotine & Tobacco Research; JAMA; Chemical Research in Toxicology; Experimental and Clinical Psychopharmacology; Pharmacology, Biochemistry and Behavior; Health Psychology and others.

Federal Research Funding

National Institute on Drug Abuse: 1981-present
National Institute on Alcoholism and Alcohol Abuse (1996-2001)
Department of Veterans Affairs Merit Review Program (1983-2003)

Patents

Rose JE, Jarvik ME and Rose KD. Method and apparatus for aiding in the reduction of the incidence of tobacco smoking. U.S. Patent Nos. 4,920,989 4,953,572 and 5,016,652.

Rose JE. Aerosol for use in the reduction of tobacco smoking. U.S. Patent No. 4,715,387.

Rose JE. Smoking of regenerated tobacco smoke. U.S. Patent Nos. 4,846,199 and 4,945,928.

Rose JE and Levin ED. Agonist-antagonist combination to reduce the use of nicotine and other drugs. U.S. Patent Nos. 5,316,759 and 5,574,052.

Rose JE and Behm FM. Low tar and nicotine cigarette adapted to provide enhanced smoking satisfaction. U.S. Patent No. 5,383,478.

Rose JE, Behm FM. and Turner J. Dry powder delivery system. U.S. Patent No. 5,441,060.

Rose, JE and Behm FM. Non-nicotine smoking cessation aid. U.S. Patent 5,893,371.

Westman EC, Rose JE and Tomlin KF. Solution containing nicotine. U.S. Patent No. 6,211,194.

Publications

1. Rosen SD, Simpson DL, **Rose JE** and Barondes SH. Carbohydrate-binding protein from *Polysphondylium pallidum* implicated in intercellular adhesion. Nature, 252:149-150, 1974.
2. **Rose JE** and Fantino EF. Conditioned reinforcement and discrimination in second-order schedules. Journal of the Experimental Analysis of Behavior, 29:393-418, 1978.
3. **Rose JE** and Fantino EF. Self-punitive behavior in humans: Effects of a self-fulfilling prophecy. Learning and Motivation, 12:214-238, 1981.
4. **Rose JE**, Lafer RL and Jarvik ME. A smoke-mixing device for measuring nicotine preference. Behavior Research Methods and Instrumentation, 14:501-503, 1982.
5. Gritz ER, **Rose JE** and Jarvik ME. Regulation of tobacco smoke intake with paced cigarette presentation. Pharmacology Biochemistry and Behavior, 18:457-463, 1983.
6. **Rose JE**, Ananda S and Jarvik ME. Cigarette smoking during anxiety-provoking and monotonous tasks. Addictive Behaviors, 8:353-359, 1983.
7. **Rose JE**. Analysis of reinforcement by varying smoke component concentrations. In: Measurement in the Analysis and Treatment of Smoking Behavior, edited by J Grabowski and CS Bell. Rockville, MD: Department of Health and Human Services, pp. 39-50, 1983.

8. Jarvik ME, Gritz ER and **Rose JE**. Cigarette smoking behavior in conjoined twins. Acta Geneticae Medicae et Gemollogiae, 32(3/4):239-243, 1983.
9. **Rose JE**, Jarvik ME and Ananda S. Nicotine preference increases after cigarette deprivation. Pharmacology Biochemistry and Behavior, 20:55-58, 1984.
10. **Rose JE**. Discriminability of nicotine in tobacco smoke: Implications for titration. Addictive Behaviors, 9:189-193, 1984.
11. **Rose JE**, Zinser MC, Tashkin DP, Newcomb R and Ertle A. Subjective response to cigarette smoking following airway anesthetization. Addictive Behaviors, 9:211-215, 1984.
12. **Rose JE**, Jarvik ME and Rose KD. Transdermal administration of nicotine. Drug and Alcohol Dependence, 13:209-213, 1984.
13. Mintz J, Boyd G, **Rose JE**, Charuvastra VC and Jarvik ME. Alcohol increases cigarette smoking: A laboratory demonstration. Addictive Behaviors, 10:203-207, 1985.
14. **Rose JE**, Herskovic JE, Trilling Y and Jarvik ME. Transdermal nicotine reduces cigarette craving and nicotine preference. Clinical Pharmacology and Therapeutics, 38:450-456, 1985.
15. **Rose JE**, Tashkin DP, Ertle A, Zinser MC and Lafer R. Sensory blockade of smoking satisfaction. Pharmacology Biochemistry and Behavior, 23:289-293, 1985.
16. Herskovic JE, **Rose JE** and Jarvik ME. Cigarette desirability and nicotine preference in smokers. Pharmacology Biochemistry and Behavior, 24:171-175, 1986.
17. **Rose JE**. Cigarette smoking blocks caffeine-induced arousal. Alcohol and Drug Research, 7:49-55, 1986.
18. **Rose JE**. Transdermal nicotine as a strategy for nicotine replacement. In: The Pharmacologic Treatment of Tobacco Dependence: Proceedings of the World Congress, November 4-5, 1985, edited by JK Okene. Cambridge, MA: Institute for the Study of Smoking Behavior and Policy, pp. 158-166, 1986.
19. Henningfield JE, Goldberg SR, Herning RI, Jasinski DR, Lukas SE, Miyasato K, Nemeth-Coslett R, Pickworth WB, **Rose JE**, Sampson A. Human studies of the behavioral pharmacological determinants of nicotine dependence. NIDA Research Monograph, 67:54-65, 1986.
20. **Rose JE**, Wu T, Djahed B and Tashkin DP. Noninvasive measurement of smokers' tar and nicotine intake. Behavior Research Methods, Instruments and Computers, 19:295-299, 1987.

21. **Rose JE**. The role of upper airway stimulation in smoking: In: Nicotine Replacement in the Treatment of Smoking: A Critical Evaluation, edited by OF Pomerleau and CS Pomerleau. New York: Alan R. Liss, Inc., pp. 95-106, 1988.
22. **Rose JE** and Hickman C. Citric acid aerosol as a potential smoking cessation aid. Chest, 92:1005-1008, 1988.
23. Jarvik ME, Caskey NH, **Rose JE**, Herskovic JE and Sadeghpour M. Anxiolytic effects of smoking associated with four stressors. Addictive Behaviors, 14:379-386, 1989.
24. **Rose JE** and Behm FM. Refined cigarette smoke as a means to reduce nicotine intake. Pharmacology Biochemistry & Behavior, 28:305-310, 1987.
25. Gritz ER, Ippoliti A, Jarvik ME, **Rose JE**, Shiffman S, Harrison A and Van Vunakis H. The effect of nicotine on the delay of gastric emptying. Alimentary Pharmacology & Therapeutics, 2: 173-178, 1988.
26. Wu T, Tashkin DP, **Rose JE** and Djahed B. Influence of marijuana potency and amount of cigarette consumed on marijuana smoking pattern. Journal of Psychoactive Drugs, 20: 43-46, 1988.
27. Gorelick DA, **Rose JE** and Jarvik ME. Effect of naloxone on cigarette smoking. Journal of Substance Abuse, 1:153-159, 1989.
28. Wu T, Tashkin DP, Djahed B and **Rose JE**. Pulmonary hazards of smoking marijuana as compared with tobacco. The New England Journal of Medicine, 318: 347-351, 1988.
29. **Rose JE**, Sampson A, Levin ED and Henningfield JE. Mecamylamine increases nicotine preference and attenuates nicotine discrimination. Pharmacology Biochemistry & Behavior, 32:933-938, 1989.
30. Pomerleau OF, Pomerleau CS and **Rose JE**. Controlled dosing of nicotine: A review of problems and progress. Annals of Behavioral Medicine, 11:158-163, 1990.
31. Behm F, Levin ED, Lee YK and **Rose JE**. Low-nicotine smoke aerosol reduces desire for cigarettes. Journal of Substance Abuse, 2:237-247, 1990.
32. Levin ED, **Rose JE** and Behm F. Controlling puff volume without disrupting smoking topography. Behavior Research Methods Instruments & Computers, 21:383-386, 1989.
33. Levin ED, McGurk SR, **Rose JE** and Butcher LL. Reversal of a mecamylamine-induced cognitive deficit with the D2 agonist, LY171555. Pharmacology Biochemistry & Behavior, 33:919-922, 1989.

34. Pomerleau OF, **Rose JE**, Pomerleau CS and Majchrzak MJ. A noninvasive method for delivering controlled doses of nicotine via cigarette smoke. Behavior Research Methods, Instruments, & Computers, 21:598-602, 1989.
35. Levin ED, Behm F and **Rose JE**. Development of a citric acid aerosol as a smoking cessation aid. Drug and Alcohol Dependence, 25:273-279, 1990.
36. **Rose JE**, Levin ED, Behm F and Adivi C. Transdermal nicotine facilitates smoking cessation. Clinical Pharmacology and Therapeutics, 30: 323-330, 1990.
37. Levin ED, **Rose JE**, McGurk SR and Butcher LL. Characterization of the cognitive effects of combined muscarinic and nicotinic blockade. Behavioral and Neural Biology, 53:103-112, 1990.
38. Levin E, Lee C, **Rose JE**, Reyes A, Ellison G, Jarvik M, and Gritz E. Chronic nicotine and withdrawal effects on radial-arm maze performance. Behavioral and Neural Biology, 53:269-276, 1990.
39. Levin, ED, Behm FM and **Rose JE**. The use of flavor in cigarette substitutes. Drug and Alcohol Dependence, 26:155-160, 1990.
40. Levin ED, McGurk SR, **Rose JE** and Butcher LB. Cholinergic-dopaminergic interactions in cognitive performance. Behavioral and Neural Biology, 54:271-299, 1990.
41. Bennett RH, Cherek DR, Roache JD and **Rose JE**. Effects of controlled nicotine doses upon punished and non-punished responding in humans. In: Problems of Drug Dependence 1989, NIDA Research Monograph 95, edited by LS Harris. Rockville, MD: National Institute on Drug Abuse, pp. 438-439, 1990.
42. Levin ED and **Rose JE**. Anticholinergic sensitivity following chronic nicotine administration as measured by radial-arm maze performance in rats. Behavioural Pharmacology, 1:511-520, 1990.
43. **Rose JE**. Transdermal nicotine and nicotine nasal spray as smoking cessation treatments. In: The Clinical Management of Nicotine Dependence, edited by JA Cocores. New York: Springer-Verlag, 1991, pp.196-207.
44. **Rose JE** and Behm FM. Psychophysiological interactions between caffeine and nicotine. Pharmacology Biochemistry & Behavior, 38:333-337, 1990.
45. **Rose JE** and Levin ED. Inter-relationships between conditioned and primary reinforcement in the maintenance of cigarette smoking. British Journal of Addiction, 86:605-609, 1991.
46. Cherek DR, Bennett RH, Roache JD and **Rose JE**. Effects of spirometric administration of tobacco smoke containing varying amounts of nicotine on physiological measures and subjective ratings. Behavioural Pharmacology, 2:15-22, 1991.

47. Levin ED and **Rose JE**. Interactive effects of D1 and D2 agonists with scopolamine on radial-arm maze performance. **Pharmacology Biochemistry & Behavior**, 38:243-246, 1991.
48. Levin ED and **Rose JE**. Nicotinic and muscarinic interactions and choice accuracy in the radial-arm maze. Brain Research Bulletin, 27:125-128, 1991.
49. Levin ED, **Rose JE**, Behm F and Caskey NH. The effects of smoking-related sensory cues on psychological stress. Pharmacology Biochemistry & Behavior, 39:265-268, 1991.
50. Tashkin, DP, Gliederer F, **Rose JE**, Chang P, Hui KK, Yu, JL and Wu T. Effects of varying marijuana smoking profile on deposition of tar and absorption of CO and delta-9-THC. Pharmacology Biochemistry & Behavior, 40:651-656, 1991.
51. Tashkin, DP, Gliederer F, **Rose JE**, Chang P, Hui KK and Yu, JL. Tar, CO and delta-9-THC delivery from first and second halves on a marijuana cigarette. Pharmacology Biochemistry & Behavior, 40:657-661, 1991.
52. **Rose JE** and Levin ED. Concurrent agonist-antagonist administration for the analysis and treatment of drug dependence. Pharmacology Biochemistry & Behavior, 41:219-226, 1991.
53. Levin Ed and **Rose JE**. Cognitive effects of D1 and D2 interactions with nicotinic and muscarinic systems. In: Neurotransmitter Interactions and Cognitive Function, edited by ED Levin, MW Decker & LL Butcher. Boston: Berkhauser, 1992.
54. Levin, ED, Briggs, SJ, Christopher NC and **Rose JE**. Persistence of chronic nicotine-induced cognitive facilitation. Behavioral and Neural Biology, 58:152-158, 1992.
55. Behm FM, Schur C, Levin ED, Tashkin DP and **Rose JE**. Clinical evaluation of a citric acid inhaler for smoking cessation. Drug and Alcohol Dependence, 31:131-138, 1993.
56. Levin ED, Briggs SJ, Christopher NC and **Rose JE**. Sertraline attenuates hyperphagia following nicotine withdrawal. Pharmacology Biochemistry & Behavior, 44:51-61, 1993.
57. **Rose JE**, Behm FM and Levin ED. The role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacology Biochemistry & Behavior, 44:891-900, 1993.
58. Levin ED, Briggs SJ, Christopher NC and **Rose JE**. Chronic nicotinic stimulation and blockade effects on working memory. Behavioural Pharmacology, 4:179-182, 1993.
59. Westman EC, Levin ED and **Rose JE**. Effectiveness of the nicotine patch in smoking cessation: A randomized controlled trial with telephone counseling. Archives of Internal Medicine, 153:1917-1923, 1993.
60. Levin ED, Behm FM, Carnahan E, LeClair R, Shipley R and **Rose JE**. Clinical trials using ascorbic acid aerosol to aid smoking cessation. Drug and Alcohol Dependence, 33:211-223, 1993.

61. Lane JD, Westman EC, Ripka GV, Wu J, Chiang, C and Rose, JE. Pharmacokinetics of a transdermal nicotine patch compared to nicotine gum. Drug Development and Industrial Pharmacy, 19(16):1999-2010, 1993.
62. Levin ED, Christopher NC, Briggs SJ and **Rose JE**. Chronic nicotine reverses working memory deficits caused by lesions of the fimbria or medial basolocortical projection. Cognitive Brain Research, 1:137-143, 1993.
63. Levin ED, Briggs SJ, Christopher NC and **Rose JE**. Prenatal nicotine exposure and cognitive performance in rats. Neurotoxicology and Teratology, 15:251-260, 1993.
64. **Rose JE**, Levin ED and Benowitz N. Saliva nicotine as an index of plasma levels in skin patch users. Therapeutic Drug Monitoring, 15:431-435, 1993.
65. Brucato FH, Levin ED, **Rose JE** and Swartzwelder HS. Intracerebroventricular nicotine and mecamylamine alter radial-arm maze performance in rats. Drug Development Research, 31:18-23, 1994.
66. Levin ED, Westman EC, Stein RM, Carnahan E, Sanchez M, Herman S, Behm FM and **Rose JE**. Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms and attenuates rewarding effects of smoking. Journal of Clinical Psychopharmacology, 14:41-49 1994.
67. **Rose JE** and Behm FM. Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms. Drug and Alcohol Dependence, 34:225-229, 1994.
68. Behm, FM and **Rose, JE**. Reducing craving for cigarettes while decreasing smoke intake using capsaicin-enhanced low-tar cigarettes. Experimental and Clinical Psychopharmacology, 2:143-153, 1994.
69. **Rose JE**, Behm FM, Westman EC, Levin ED, Stein RM and Ripka GV. Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical Pharmacology & Therapeutics, 56:86-99, 1994.
70. **Rose JE**, Behm FM, Westman EC, Levin ED, Stein, RM, Lane JD and Ripka GV. Combined effects of nicotine and mecamylamine in attenuating smoking reward. Experimental & Clinical Psychopharmacology, 2:1-17, 1994.
71. **Rose, JE**. Nicotine delivery systems for smoking cessation. In: The Encyclopedia of Drugs and Alcohol, edited by JH Jaffe. New York: MacMillan Co., 1995.
72. Beckham JC, Roodman AA, Shipley RH, Hertzberg MA, Cunah GH Kudler HS Levin ED, **Rose JE** and Fairbank JA. Smoking in Vietnam combat veterans with posttraumatic stress disorder. Journal of Traumatic Stress, 8:461-472, 1995.

73. Levin ED and **Rose JE**. Acute and chronic nicotinic interactions with dopamine systems and working memory performance. In: Diversity of Interacting Receptors, New York Academy of Sciences, vol. 757, edited by L.G Abood and A. Lajtha, pp. 245-252, 1995.
74. **Rose JE**, Levin ED, Behm FM, Westman EC, Stein RM, Lane JD and Ripka GV. Combined administration of agonist-antagonist as a method of regulating receptor activation. In: Diversity of Interacting Receptors, New York Academy of Sciences, vol. 757, edited by L.G Abood and A. Lajtha, pp. 218-221, 1995.
75. Levin ED, **Rose JE** and Abood LG Effects of nicotinic dimethylaminoethyl esters on working memory performance of rats in the radial arm maze. Pharmacology Biochemistry & Behavior, 51:369-373, 1995.
76. Westman EC, Behm FM and **Rose JE**. Airway sensory replacement combined with nicotine replacement for smoking cessation: A randomized, placebo controlled trial using a citric acid inhaler. Chest, 107:1358-1364, 1995.
77. Lane JD, Lefebvre JC and **Rose JE**. Effects of cigarette smoking on perception of thermal pain. Experimental & Clinical Psychopharmacology, 3:140-147, 1995.
78. Lane JD and **Rose JE**. Effects of caffeine intake on smoking behavior in the natural environment. Experimental & Clinical Psychopharmacology, 3:49-55, 1995.
79. Westman EC, Levin ED and **Rose JE**. Nicotine as a therapeutic drug. North Carolina Medical Journal, 56:2-5, 1995.
80. **Rose JE** and Behm FM. There is more to smoking than the CNS effects of nicotine. In: Effects of Nicotine on Biological Systems II, edited by PBS Clarke, M Quik, F Adlkofer and K Thureau. Basel: Birkhauser Verlag, 1995, pp.239-246.
81. McEvoy J, Freudenreich O, McGee M, VanderZwaag C, Levin E and **Rose J**. Clozapine decreases smoking in patients with chronic schizophrenia. Biol. Psychiatry, 37:550-552, 1995.
82. McEvoy JP, Freudenreich O, Levin ED and **Rose JE**. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology, 119:124-126, 1995.
83. **Rose JE**. Nicotine addiction and treatment. Annual Review of Medicine, 47:493-507, 1996.
84. Westman, EC, Behm, FM and **Rose JE**. Airway sensory replacement as a treatment for smoking cessation. Drug Development Research, 38:257-262, 1996.
85. Westman EC, Behm FM and **Rose JE**. Dissociating the nicotine and airway sensory effects of smoking. Pharmacology Biochemistry & Behavior, 53:309-315, 1996.
86. Levin ED, Wilson W, **Rose JE** and McEvoy JP. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology, 15:429-436, 1996.

87. Conners CK, Levin ED, Sparrow E, Hinton SC, Erhardt D, Meck WH, **Rose JE** and March J. Nicotine and attention in adult attention deficit hyperactivity disorder ADHD. Psychopharmacology Bulletin, 32:67-73, 1996.
88. Levin ED, Conners CK, Sparrow E, Hinton SC, Meck WH, **Rose JE**, Erhardt D, and March J. Nicotine effects on adults with attention deficit/hyperactivity disorder. Psychopharmacology, 123:55-63, 1996.
89. Westman EC, and **Rose JE**. Do heavy smokers need a higher replacement dose of nicotine to quit? JAMA (letter), 275:1882, 1996.
90. Shipley, R and **Rose JE**. Quit Smart Stop Smoking Guide. Durham NC:JB Press; 1997.
91. **Rose JE**, Westman EC and Behm FM. Combination nicotine /mecamylamine treatment for smoking cessation. Drug Development Research, 38:243-256, 1996.
92. Lane JD, Opara EC, **Rose JE**, Behm FM. Quitting smoking raises whole blood glutathione. Physiology and Behavior, 60:1379-1381, 1996.
93. **Rose JE**. Tobacco industry science: To be encouraged or extinguished? Addiction, 92:521-529.
94. Westman EC, Behm FM, Simel DL and **Rose JE**. Smoking behavior on the first day of a quit attempt predicts long-term abstinence. Archives of Internal Medicine, 157:335-340, 1997.
95. **Rose JE** and Corrigan WC. Nicotine self-administration in animals and humans: Similarities and differences. Psychopharmacology, 130:28-40, 1997.
96. **Rose JE**, Behm, FM, and Westman EC. Nicotine/mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Experimental and Clinical Psychopharmacology, 6:1-13, 1998.
97. **Rose, JE**, Westman, EC, Behm, FM, Johnson, MP, and Goldberg, JS. Blockade of smoking satisfaction using the peripheral nicotinic antagonist trimethaphan. Pharmacology Biochemistry & Behavior, 62:165-172, 1999.
98. Brauer LH, Behm FM, Westman EC, Patel P, **Rose JE**. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology, 143 4: 339-346, 1999.
99. **Rose JE**, Behm FM, Westman EC, and Coleman RE. Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: Implications for addiction. Drug & Alcohol Dependence, 56:99-107, 1999.
100. **Rose JE**, Behm FM, Westman, EC, and Johnson M. Dissociating nicotine and non-nicotine components of cigarette smoking. Pharmacology Biochemistry & Behavior, 67:71-81, 2000.

101. **Rose JE**. Nicotine delivery systems for smoking cessation. In: The Encyclopedia of Drugs, Alcohol, and Addictive Behavior, revised edition, edited by R Carson-DeWitt. New York: MacMillan Co., 2000.
102. Westman EC, Tomlin KF and **Rose JE**. Combining the nicotine inhaler and nicotine patch for smoking cessation. American Journal of Health Behavior, 24:114-119, 2000.
103. Levin, ED, Mead T, Rezvani AH, **Rose JE**, Gallivan C and Gross R. The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs. food self-administration in rats. Physiology & Behavior, 71:565-570, 2000.
104. **Rose JE**, Behm FM and Westman EC. Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking. Pharmacology Biochemistry & Behavior, 68:187-197, 2001.
105. Brauer LH, Behm FM, Lane JD, Westman EC, Perkins C and **Rose JE**. Individual differences in smoking reward from denicotinized cigarettes. Nicotine and Tobacco Research, 3:101-109, 2001.
106. **Rose JE**. Evaluation of pharmacologic treatments for smoking cessation. In ED Levin (ed.) Nicotinic Receptors in the Nervous System. Boca Raton, FL: CRC Press, 2001.
107. **Rose JE**, Behm, FM, Ramsey C and Ritchie JC, Jr. Platelet monoamine oxidase, smoking cessation and tobacco withdrawal symptoms. Nicotine and Tobacco Research, 3:383-390, 2001.
108. Westman EC, Tomlin KF, Perkins CF and **Rose JE**. Oral nicotine replacement for smoking cessation: A pilot tolerability study. Nicotine & Tobacco Research, 3:391-396, 2001.
109. Brauer LH, Cramblett MJ, Paxton DA and **Rose JE**. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology, 159:31-37, 2001.
110. Blomqvist O, Hernandez-Avila CA, Van Kirk J, **Rose JE** and Kranzler HR. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcoholism: Clinical and Experimental Research, 26:326-331, 2002.
111. **Rose JE**, Behm, FM, Westman, EC, Mathew RJ, London, ED, Hawk TC, Turkington, TG and Coleman RE. PET Studies of the influences of nicotine on neural systems in cigarette smokers. American Journal of Psychiatry, 160:323-333, 2003.
112. Yang YK, McEvoy JP, Wilson WH, Levin ED and **Rose JE**. Reliabilities and intercorrelations of reported and objective measures of smoking in patients with schizophrenia. Schizophrenia Research, 60:9-12, 2003.
113. Levin ED, Rezvani AH, Montoya D, **Rose JE** and Swartzwelder HS. Adolescent-onset nicotine self-administration modeled in female rats. Psychopharmacology, 169:141-149, 2003.

114. **Rose JE**, Behm FM, Westman EC, and Bates JE. Mecamylamine acutely increases human IV nicotine self-administration. Pharmacology Biochemistry & Behavior, 76:307-313, 2003.
115. **Rose JE**, Behm FM, Westman EC, Bates JE and Salley A. Pharmacologic and sensorimotor components of satiation in cigarette smoking. Pharmacology Biochemistry & Behavior, 76:243-250. 2003.
116. **Rose JE**, Brauer LH, Behm FM, Cramblett M, Calkins K, and Lawhon D. Psychopharmacologic interactions between nicotine and ethanol. Nicotine and Tobacco Research, 1:133-144, 2004.
117. **Rose JE** and Behm FM. Effects of low nicotine content cigarettes on smoke intake. Nicotine and Tobacco Research, 6:309-319, 2004.
118. **Rose JE** and Behm FM. Extinguishing the rewarding value of smoke cues: pharmacologic and behavioral treatments. Nicotine and Tobacco Research, 6: 523-532, 2004.
119. McClernon FJ & **Rose JE**. Mecamylamine moderates cue-induced emotional responses in smokers. Addictive Behaviors, 30, 741-753, 2005.
120. **Rose JE**. (2005). Ethics of tobacco company funding. Science, 308(5722), 632.
121. Beckham JC, Feldman ME, Mozley SL, Vrana SR, Erkanli A, Clancy CP., & **Rose JE**. (2005). Immediate antecedents of cigarette smoking in smokers with and without posttraumatic stress disorder. Journal of Experimental and Clinical Psychopharmacology, 13, 218-228.
122. FJ McClernon, Huettel SA, **Rose JE**. Abstinence-induced changes in self-report craving correlate with event-related fMRI responses to smoking cues. Neuropsychopharmacology, 30:1940-1947, 2005.
123. **Rose JE**, Behm FM, Westman EC, Kukovich P. Pre-cessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine & Tobacco Research, 8:89-101, 2006.
124. **Rose JE**. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology, 16:1-12, 2006.
125. Marx CE, Trost WT, Shampine L, Behm FM, Giordano LA, Massing MW, **Rose JE**. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (2006) Jan. 10 (online).
126. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Corrigan WA, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, **Rose JE**, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM. Guidelines for nicotine dose selection for in vivo research. Psychopharmacology, 2006 Aug. 9; [Epub ahead of print].

127. **Rose JE**. Nicotine replacement therapies and other nicotinic agents. Medication Treatments for Nicotine Dependence. Taylor & Francis LLC-CRC Press, 2006.
128. McClernon FJ, Hiott FB, Westman EC, **Rose JE**, Levin ED. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled study. Psychopharmacology 189 (1)125-133 Published online: 2006 Sept. 15.
129. **Rose JE**, Behm FM, Salley AN, Bates JE, Coleman RE, Hawk TC. Regional brain activity correlates of nicotine dependence. Neuropsychopharmacology 2007 Dec;32(12):2441-52. Epub 2007 Mar 14.
130. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, **Rose JE**. Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genetics, 8:10, 3 April 2007.
131. McClernon FJ, Westman EC, **Rose JE**, Lutz AM. The effects of foods, beverages and other factors on cigarette palatability. Nicotine and Tobacco Research, 9:505-510, 2007.
132. McClernon FJ, Hiott FB, Liu J, Salley AN, Behm FM, **Rose JE**. Selectively reduced responses to smoking cues in amygdala following extinction-based smoking cessation: Results of a preliminary fMRI study. Addiction Biology, 12:505-512, 2007.
133. Pettiford J, Kozink RV, Lutz AM, Kollins SH, **Rose JE**, McClernon, FJ. Increases in impulsivity following smoking abstinence are related to baseline nicotine intake and boredom susceptibility. Addictive Behaviors, 3:2351-2357, 2007.
134. McClernon FJ, Hutchinson KE, **Rose JE**, Kozink RV. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology (Berl), 194:433-441, 2007.
135. **Rose JE**. Multiple brain pathways and receptor subtypes in tobacco addiction. Biochemical Pharmacology, 74:1263-1270, 2007.
136. McClernon, FJ, Kollins SH, Lutz, AM, Fitzgerald DP, Murray DW, Redman C, **Rose JE**. Effects of smoking abstinence on adult smokers with and without attention deficit hyperactivity disorder: Results of a preliminary study. Psychopharmacology 197:195-205, 2008.
137. Uhl GR, Liu Q-R, Drgon T, Johnson C, Walther D, **Rose JE**, David SP, Niaura R Lerman C. Molecular genetics of successful smoking cessation: Convergent genome-wide association study results Archives of General Psychiatry, 165(6):683-693, 2008.
138. **Rose JE**. Pre-cessation varenicline treatment vs. post-cessation NRT: An uneven playing field. Thorax, in press, 2008.

139. **Rose JE**. Disrupting nicotine reinforcement: From cigarette to brain. Addiction Reviews, in press, 2008.
140. **Rose JE**. New findings in nicotine addiction and treatment. In: Caggiula AR & Bevins R (eds.), The Motivational Impact of Nicotine and its Role in Tobacco Use, in press, 2008.
141. McClernon FJ, Kozink RV and **Rose JE**. Individual differences in nicotine dependence, withdrawal symptoms, and sex predict transient fMRI-BOLD responses to smoking cues. Neuropsychopharmacology, 33:2148-2157, 2008.
142. Becker KM, **Rose JE** and Albino AP. A randomized trial of nicotine replacement therapy in combination with reduced-nicotine cigarettes for smoking cessation. Nicotine and Tobacco Research, 10:1139-1148, 2008.
143. Uhl GR, Drgon T, Johnson C and **Rose JE**. Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials The Pharmacogenomics Journal, in press, 2008.
144. Levin ED, A Petro, N Pollard, NC Christopher, M Strauss, J Avery, J Nicholson, **JE Rose** and AH Rezvani. Nicotinic $\alpha 7$ or $\beta 2$ -containing receptor knockout: effects on radial-arm maze learning and long-term nicotine consumption in mice. Behavioural Brain Research, doi:10.1016/j.bbr.2008.08.048, 2008.
145. Brody AL, Mandelkern MA, Costello, MR, Abrams AL, Scheibel D, Farahi J, London ED, Olmstead RE, **Rose JE**, Mukhin AG. Brain nicotinic acetylcholine receptor occupancy; Effect of smoking a de-nicotinized cigarette. International Journal of Neuropsychopharmacology, in press, 2008.
146. Levin ED, S Slade, M Johnson, A Petro, K Horton, P Williams, AH Rezvani and **JE Rose**. Ketanserin, a 5-HT₂ antagonist, decreases nicotine self-administration in rats. European Journal of Pharmacology, doi: 10.1016/j.ejphar.2008.10.016, 2008.
147. Dehkordi O, **Rose JE**, Balan KV, Prabha K, Millis RM and Jayam-Trouth A. Neuroanatomical Relationships of Substance P Immunoreactive Intrapulmonary C-Fibers and Nicotinic Cholinergic Receptors. Journal of Neuroscience Research, in press.
148. McClernon, FJ, Kozink, RV, Lutz, AM, & Rose, JE (2008, accepted). 24-hr smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum. Psychopharmacology, in press.
149. **Rose JE**, Herskovic JE, Behm FM and Westman EC. Pre-cessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment. Nicotine & Tobacco Research, under review.